ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO772

Augmented Foam Sclerotherapy with Laser Treatment for Cystic Disease from In Vitro Sclerosant Screening Platform

Session Information

  • Bioengineering
    October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bioengineering

  • 300 Bioengineering


  • Jeong, Soohyun, Seoul National University, Seoul, Korea (the Republic of)
  • Park, Min hee, Seoul National University, Seoul, Korea (the Republic of)
  • Lee, Kangwon, Seoul National University, Seoul, Korea (the Republic of)

Sclerotherapy has been empirically used in cyst ablation as managemental treatment of polycystic kidney. However valid, clinical reports and research mostly rely on the ex-vivo platform and desultory treatment methods. To standardize the sclerotherapy and minimize the complication of usage of sclerotherapy treatment to cystic disease, in vitro platform from which the sclerosing solution be tested and enhanced sclerosing treatment methods for cyst ablation must be studied.


The transwell system and collagen embedded cells were used in this study as the in vitro platform. The cellular membrane-disrupting effect was quantitatively measured in vitro by LDH assays which have been not tried before to our knowledge. Screening of sclerosing solution was conducted by measuring LDH level on this system. Photochemical tissue bonding from foam-delivered rose Bengal stains was carried out using 532nm green laser and two-photon laser. Sclerosing effect and degree of inflammation from the augmented foam sclerosant was studied in vivo.


We found that the suggested in vitro platform reflect differential sclerosing properties from different sclerosing material than conventional cell analysis. In this study, we obtained the improved sclerosing foam with greater sclerosing and retention properties. This sclerosant was optimized with polidocanol, glycerol and rose bengal sufficient for cyst ablation and laser-assisted photochemical tissue bonding of the cystic membrane.


To our knowledge, our study is the first in suggesting sclerotherapy with photochemical tissue bonding combined treatment methods, along with the suggested foam sclerosant screening platform. We believe our research would extend possible treatment option for cyst management in polycystic kidney, as well as the promoting the development of safer, better sclerosing materials.